59 results about "Retinal tissue" patented technology

The present invention belongs to the field of genetic engineering and biotechnology, and relates to the screening, construction and application of a modified type of AAV-8 serotype for gene targeting and expression. The modified type of the AAV-8 serotype of the present invention inserts 10 amino acid sequences between the 590th amino acid and the 591st amino acid of the AAV-8 serotype capsid protein sequence as shown in SEQ ID NO.2, wherein the 3rd to 9th amino acids are amino acid sequences obtained by screening. The modified serotype of the present invention targets each layer of the retina, and the fluorescence effect after infection is stronger, and it can be clearly and intuitively observed that the exogenous gene can be efficiently expressed in each layer of the retina of the targeted tissue, including the retinal ganglion cell layer, the inner nuclear layer, the outer nuclear layer, the photoreceptor cell layer and the retinal pigment epithelial cell layer, and has better and more targeted tissue expression than the wild-type serotype when the same amount of virus is used.

An object of the present invention is to provide a cell population suitable for transplant of retinal tissue and a method of production thereof. The present invention provides a cell population for transplant, comprising retinal cells with a modified bipolar cell-regulating gene and a method of production thereof.

The method comprises the following steps: fixing with a pre-fixing solution, wrapping and forming with a solid agent, fixing with a fixing solution, embedding with an embedding agent, decomposing melanin with a melanin decomposing solution, pre-decoloring with a pre-decoloring solution, decoloring with a decoloring solution, and eluting with a rinsing solution. The invention provides a melanin removing method capable of effectively avoiding retina RPE layer cell exfoliation, protein denaturation and nucleic acid degradation. The method mainly comprises the following steps: keeping the original state of tissue cells by adopting a pre-fixing solution, keeping the complete tissue structure by adopting a solid agent, decomposing melanin particles by adopting a melanin decomposing solution composed of various extracts, separating melanin by adopting a pre-decoloring solution and a decoloring solution, eluting the melanin decomposed on the surface of the tissue by adopting a rinsing solution, and the like. On the premise that the retina tissue structure is intact and protein, nucleic acid and cell structures on the surface of the tissue section are not damaged, melanin particles in the tissue section are effectively decomposed, the biological activity of various organelles on the surface of the section is kept, and the requirements of subsequent chemical staining of various tissues are met.

The present invention provides a method for producing a retinal progenitor cell, including (1) a first step of subjecting pluripotent stem cells to floating culture in a serum-free medium to form an aggregate of pluripotent stem cells, and (2) a second step of subjecting the aggregate formed in step (1) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog signal transduction pathway but containing a substance acting on the BMP signal transduction pathway, thereby obtaining an aggregate containing retinal progenitor cells.

The present invention provides a method for producing retinal cells or a retinal tissue, comprising the following steps (1)-(3):(1) a first step of culturing human pluripotent stem cells in the absence of feeder cells and in a medium comprising a factor for maintaining undifferentiated state,(2) a second step of culturing the pluripotent stem cells obtained in the first step in suspension in the presence of a Sonic hedgehog signal transduction pathway activating substance to form a cell aggregate, and(3) a third step of culturing the aggregate obtained in the second step in suspension in the presence of a 1) a BMP signal transduction pathway activating substance to obtain an aggregate containing retinal cells or a retinal tissue.

Phase-based optoretinography (ORG) is performed using tissue velocity obtained from a modified optical coherence tomography (OCT) system. A swept-source generated OCT A-scan is used to assemble a 2-dimensional profile of the retinal tissue (B-scan) by laterally scanning the imaging beam. These B-scans can be taken at multiple time-points and assembled into a M-scan, which displays motion of a particular cross-section of retinal tissue (after correction for bulk motion). The method captures the changes between each timestep of the M-scan to deduce tissue velocities of the COST, ROST, and IS / OS, among others. An initial contraction of outer segments is detected in outer segments, followed by an elongation shortly thereafter. The tissue velocity measurements can be used to infer retinal dysfunction without the need for costly and computationally expensive scans using adaptive optics.

This invention discloses a novel structural polysaccharide SYQE3-F derived from the roots of *Tripterygium wilfordii*, its preparation method, pharmaceutical composition, and applications, belonging to the field of biomedical technology. This invention is the first to isolate and purify a homogeneous polysaccharide SYQE3-F from the roots of *Tripterygium wilfordii*, with an average molecular weight of 13.174 kDa. Its main chain consists of →4)-β-D-GlcpA-(1→) and →2)-α-D-Manp-(1→), and its side chains include t-Galp and t-Araf. This invention also discloses a pharmaceutical composition containing this polysaccharide and vitamin E. In vitro and in vivo experiments show that this polysaccharide can effectively break down choroidal occlusion barriers and significantly promote the transport of vitamin E to the target retinal tissue, providing a novel natural drug combination for the clinical treatment of DR.

In some embodiments, a system for providing a therapeutic treatment to a patient's eye includes a treatment beam source configured to transmit a treatment beam along a treatment beam path. The system further includes a processor coupled to the treatment beam source, the processor being configured to direct the treatment beam onto retinal tissue of the patient's eye and deliver a series of short duration pulses from the treatment beam onto the retinal tissue at a first treatment spot to treat the retinal tissue. In some embodiments, a pre-treatment evaluation method using electroretinography (ERG) data may be used to predict effects of treatment beams at different power values and to determine optimal power values.

The present invention relates to the application of an EphA2-specific tyrosine kinase inhibitor, ALW-II-41-27, in ophthalmic diseases. The present invention has confirmed that at a specific concentration, ALW-II-41-27 can inhibit the expression of EphA2 in the retina, reduce the damage of acute high intraocular pressure to retinal tissue, and improve the survival rate of retinal ganglion cells, thereby playing a neuroprotective role, and thus being used for the preparation of treatments for preventing and treating acute high intraocular pressure or glaucoma.

The utility model aims to provide an auxiliary device for taking out an eyeball retina specimen of an experimental mouse, which relates to the technical field of medical instruments and is characterized in that during use, a cornea of a taken-down eyeball of the mouse is placed below an operating cylinder upwards, and an arc-shaped sheet is controlled to clamp the cornea by rotating a cover plate of a reducing mechanism; mouse eyeballs of different sizes can be fixed through the diameter changing mechanism, in the moving process, the arc-shaped piece abuts against the blade to move towards the circle center of the base to be attached to the cornea, the mounting ring is rotated to cut the cornea, then the clamping mechanism slides downwards to be close to and clamp the cornea and the crystalline lens, and the cornea and the crystalline lens are separated. Then, the optic cup-shaped tissue with the cornea and the crystalline lens removed is reversed, the clamping rod continues to be used for fixing the optic nerve, the cup opening of the optic cup-shaped tissue abuts against the arc-shaped piece, then the clamping rod translates downwards, and the internal retina tissue is completely extruded out of the optic cup-shaped tissue through the innate subretinal space; therefore, an eyeball retina specimen is obtained.

Optical coherence tomography (OCT) data can be analyzed with neural networks trained on OCT data and known clinical outcomes to make more accurate predictions about the development and progression of retinal diseases, central nervous system disorders, and other conditions. The methods take 2D or 3D OCT data derived from different light source configurations and analyze it with neural networks that are trained on OCT images correlated with known clinical outcomes to identify intensity distributions or patterns indicative of different retina conditions. The methods have greater predictive power than traditional OCT analysis because the invention recognizes that subclinical physical changes affect how light interacts with the tissue matter of the retina, and these intensity changes in the image can be distinguishable by a neural network that has been trained on imaging data of retinas.

The present invention provides a method for producing a retinal progenitor cell, including (1) a first step of subjecting pluripotent stem cells to floating culture in a serum-free medium to form an aggregate of pluripotent stem cells, and (2) a second step of subjecting the aggregate formed in step (1) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog signal transduction pathway but containing a substance acting on the BMP signal transduction pathway, thereby obtaining an aggregate containing retinal progenitor cells.

The invention provides a capsid rearrangement adeno-associated virus vector and application thereof. In particular, the present invention provides a capsid rearrangement serotype based on an existing AAV. The rearrangement serotype provided by the invention has higher toxin production, high real heart rate and low immunogenicity, and has high transduction activity in human retina tissues. The invention also provides a recombinant virus vector containing the rearranged AAV capsid and application of the recombinant virus vector in disease treatment.

Provided herein are methods and systems for determining a parameter across a surface of a tissue such as a retinal tissue of an eye of a subject. In some cases, the determined parameter is tissue oxygenation which can be used for a variety of clinical applications such as diagnosing and / or modeling a disease in the subject. In some examples, the method is performed by detecting one or more optical signals from the tissue using an optical detector, and processing the detected optical signals to characterize and map the parameter across the surface of the tissue. The methods and systems provided herein can prove accurate physics-based models of parameters such as tissue oxygenation across a heterogeneous tissue surface.

The present disclosure provides methods and an apparatus for imaging and analysing images of presumed protein deposits in the retina, retinal tissue or retinal structures and discloses methods differentiating or classifying these deposits and other optical signals from retinal structures into 1) whether they contain or do not contain classes, of proteins or protein deposits called amyloids or other proteins and / or protein deposits related to neurodegenerative eye and brain disease(s): 2) which type(s) of amyloid or other proteins or protein deposits they contain, as well as 3) whether the form and / or properties of the deposit are associated with a class of diseases or with one or another specific condition(s) (or disease(s)); whether or not this is a disease or class of disease associated with the retina or more generally with the nervous system, including the brain or 4) classified as associated with one or another level of severity of condition(s), or disease(s).

A method for preventing the retinal pigment from being removed from the network, comprising the steps of pre-fixing liquid fixation, solidifying agent wrapping shaping, fixing liquid fixation, embedding agent embedding, melanin decomposition liquid decomposing melanin, pre-decoloring liquid pre-decoloring, decoloring liquid decoloring and rinsing liquid elution. A method for removing melanin is provided to effectively avoid the retinal RPE layer cell from being removed from the network, protein denaturation and nucleic acid degradation. The method mainly adopts the following steps: pre-fixing liquid to maintain the original state of tissue cells, solidifying agent to maintain the integrity of tissue structure, melanin decomposition liquid composed of various extracts to decompose melanin particles, pre-decoloring liquid and decoloring liquid to separate melanin, and rinsing liquid to elute the decomposed melanin on the surface of the tissue, etc. Under the premise of ensuring the integrity of the retinal tissue structure, not damaging the surface protein, nucleic acid and cell structure of the tissue section, effectively decomposing the melanin particles in the tissue section, maintaining the biological activity of various organelles on the section surface and meeting the needs of subsequent various histochemical staining.

The present invention provides a method for maintaining a continuous epithelial structure of a retinal tissue including culturing the retinal tissue in a medium comprising a methyl group donor or a substrate of the methyl group donor at a concentration at which cell differentiation of a neural retinal progenitor cell is suppressed, and a neurite extension inhibitor at a concentration at which neurite extension is suppressed.

A method and apparatus for identifying fundus lesions are provided. The method includes: acquiring OCT fundus images of a specific patient; using a first neural network model to determine the boundary information of retinal tissue in the OCT fundus images, and segmenting the OCT fundus images into multiple image blocks based on the boundary information of the retinal tissue; providing the multiple image blocks to a second neural network model to obtain the fundus lesion type of the specific patient; the second neural network model calculating the feature vector of each image block and the attention weight of each image block for the specified fundus lesion type, and obtaining the fused feature vector through weighted calculation to obtain the identification result for the specified fundus lesion type. The second neural network model combines spatial saliency and scanning position saliency to enhance important information in the image block group and filter out unimportant information, thereby achieving low-cost model training and application.

The present disclosure provides a method for manufacturing a cell aggregate comprising retinal tissue having a layer structure.

Provided is a method for quickly, objectively and properly evaluating the quality of a cell aggregate by determining the quality of the cell aggregate by determining an evaluation score on the basis of a determination criterion from an appropriate point of view with respect to an image of the cell aggregate.　With respect to a cell aggregate which can include a retinal tissue derived from a pluripotent stem cell, in an image region of the cell aggregate which is each of an inverted observation image of the cell aggregate and an elected observation image of the cell aggregate, a region that is determined as satisfying a color-related candidate region determination criterion for each of the inverted observation image and the elected observation image on the basis of the candidate region determination criterion is identified as a candidate region included in a region that is a candidate for a normal retinal tissue region. Subsequently, in the candidate region of each of the inverted observation image and the elected observation image, a candidate region that is determined as satisfying a brightness- and / or shape-related normal region determination criterion for each of the inverted observation image and the elected observation image is determined as the normal retinal tissue region.

The present disclosure includes: a method for producing a retinal tissue, the method comprising: (1) inoculating pluripotent stem cells to an area A having cell adhesion on a culture substrate at a density of 0.5 * 105 cells / cm < 2 > to 2.5 * 105 cells / cm < 2 >, (2) culturing the pluripotent stem cells inoculated in step (1) in a culture medium containing a ROCK inhibitor for 1-16 hours, and (3) culturing the pluripotent stem cells inoculated in step (1) in a culture medium containing a ROCK inhibitor for 1-16 hours, and (3) culturing the cells obtained after step (2) in a culture medium comprising a BMP signaling activator; a retinal tissue produced by the method; a composition comprising the retinal tissue; and the like.

A tissue transplantation resin tip and the like that allow easy transplantation of a tissue sucked inside are provided. A tissue transplantation resin tip 10 according to the present invention includes a needle tube 1 that can be inserted into an eyeball. The needle tube includes a main body portion 11 that extends linearly, and a front end portion 12 that is bent with respect to the main body portion and extends linearly, and that discharges a tissue T from a front end 121. A length L1 of the needle tube is 25 mm or more and 50 mm or less, a cross-sectional external shape of the front end portion has an oval shape having a major axis D1 of 0.8 mm or more and 1.5 mm or less, and a minor axis D2 of 0.5 mm or more and 1.0 mm or less, the front end of the front end portion is a bevel surface that extends in a direction substantially perpendicular to the main body portion, and that has a bevel angle Θ1 of 50° or more and 85° or less, the hardness of the front end portion is 0.15 N or more and 0.30 N or less, and the hardness of the center of the needle tube is 0.80 N or more and 1.50 N or less.

The invention discloses a retinal organoid culture medium and application thereof, and relates to the field of organoid culture. The culture medium comprises a basic culture medium and specific addition factors, wherein the specific addition factors comprise A8301, Forskolin, Prostaglandin E2, R-Spondin protein, Noggin protein and FGF10 (Fibroblast Growth Factor 10) protein, and the specific addition factors comprise A8301, Forskolin, Prostaglandin E2, R-Spondin protein, Noggin protein and FGF10 (Fibroblast Growth Factor 10) protein. The culture medium disclosed by the invention can be used for obtaining retina organoid culture from retina tissue culture, and is high in organoid formation rate, high in biological consistency, high in research value and wide in application prospect.

The utility model provides a kind of special stage of retinal low temperature stripping and experimental equipment, it is related to experimental apparatus field. Including stage body, the top of stage body is horizontal plane, and recess is set in its top;Ice water channel is set below recess, and ice water channel is through stage body. By setting the stage body of top surface level, and setting recess to place retina tissue, so that the stripping operation of retina can be stably carried out, and tissue is not easy to shift;Ice water channel is set for the flow of ice water mixture, keep the low temperature of stage body, since it is just below recess, and then cold quantity can be transmitted to recess faster, ice water mixture is directly replenished to keep low temperature continuously, and PBS solution is not needed to be pre-cooled frequently, so that liquid exchange is convenient and fast;Stage body can also support operator's both hands, improve operation stability.

Optical coherence tomography (OCT) data can be analyzed with neural networks trained on OCT data and known clinical outcomes to make more accurate predictions about the development and progression of retinal diseases, central nervous system disorders, and other conditions. The methods take 2D or 3D OCT data derived from different light source configurations and analyze it with neural networks that are trained on OCT images correlated with known clinical outcomes to identify intensity distributions or patterns indicative of different retina conditions. The methods have greater predictive power than traditional OCT analysis because the invention recognizes that subclinical physical changes affect how light interacts with the tissue matter of the retina, and these intensity changes in the image can be distinguishable by a neural network that has been trained on imaging data of retinas.

The utility model provides an ophthalmic surgical instrument for posterior detachment of a vitreous body, and relates to the technical field of medical instruments. The ophthalmic surgical instrument comprises an injection needle cylinder and a liquid supply pipe connected with the outlet end of the injection needle cylinder, and the end, away from the injection needle cylinder, of the liquid supply pipe is communicated with an injection needle with a silica gel soft head; a slidable piston is arranged in the injection needle cylinder, and the piston rod is detachably connected with the piston. The device is simple in structure, can be manufactured by existing medical common instruments, and can be reused, so that the cost of ophthalmologic operations is reduced; the silicone oil injection device can be connected with a silicone oil injection pipeline of the vitreous cutter for flow control and automatic injection, is stable in operation, saves manpower, and can reduce disturbance to retina tissues caused by unbalanced manual injection liquid flow.

A tissue transplantation resin tip includes a needle tube for eyeball insertion. The needle tube includes a main body portion that extends linearly. A front end portion is bent with respect to the main body portion and extends linearly, with tissue discharging from the front end. The needle tube length is 25 mm to 50 mm, the front end portion cross sectional shape is oval with a major axis D1 of 0.8 mm to 1.5 mm and a minor axis D2 of 0.5 mm to 1.0 mm. The front end of the front end portion is a bevel surface that extends in a direction substantially perpendicular to the main body portion and has a bevel angle of 50° to 85°. The front end portion hardness is 0.15 N to 0.30 N or less and the center of the needle tube hardness is 0.80 N to 1.50 N.

A composite hydrogel includes gelatin, cinnamic acid, polydopamine nanoparticles, and curcumin is provided. The gelatin is chemically cross-linked with the cinnamic acid to form cinnamic acid-modified gelatin (GelCA), and the curcumin is non-covalently linked to the polydopamine nanoparticles to form curcumin-loaded polydopamine nanoparticles (Cur@PDA). The GelCA undergoes a photo-crosslinking process and then binds with the Cur@PDA to form the composite hydrogel. A method for treating retinal tissue damage includes administering to a subject in need thereof an effective amount of the composite hydrogel.

The retina treatment-based gyromagnetic physiotherapy equipment comprises an instrument body, and a control interface is detachably mounted at the outer part of the instrument body; two discs are installed outside the instrument body, a cantilever is rotationally connected to the side, close to the discs, of the instrument body, magnets are installed at the two ends of the cantilever, two rotating motors are installed inside the instrument body, telescopic rotating rods are installed at the output ends of the rotating motors, and the ends, away from the rotating motors, of the telescopic rotating rods are connected with the cantilever. And an adjusting assembly is arranged outside the two telescopic rotating rods. Through cooperative use of the control interface, the disc, the cantilever, the magnet and the telescopic rotating rod, the special gyromagnetic physiotherapy equipment is designed, the rotating speed of a magnetic field can be controlled through the control interface, a human body is prevented from tolerating a constant rotating speed, the physiotherapy effect is improved, meanwhile, the influence of the rotating magnetic field on the retina tissue structure is simulated, and the effect of the rotating magnetic field on the retina tissue structure is simulated. The principle of physical therapy is revealed.

To provide recombinant adeno-associated viruses (rAAVs) having capsid proteins engineered to include amino acid sequences that confer and / or enhance desired properties.SOLUTION: Provided are engineered capsid proteins comprising peptide insertions from heterologous proteins inserted within or near variable region IV (VR-IV) of virus capsid, such that the insertion is surface exposed on the AAV particle. The invention also provides capsid proteins that direct rAAVs to target tissues, in particular, capsid proteins comprising peptides derived from erythropoietin or dynein that are inserted into surface-exposed variable regions and target rAAVs to retinal tissue and / or neural tissue, including a central nervous system, and deliver therapeutics for treating neurological and / or eye disorders.SELECTED DRAWING: Figure 1